ERp57-deficient cancer cells treated with anthracyclines are unable to elicit anticancer immune responses and become resistant to anthracycline chemotherapy in vivo because CRT translocation is inhibited and immunogenic cell death is abolished 58. The gene discussed is PDIA3; the disease is cancer.